Advertisement

Acta Neurochirurgica

, Volume 68, Issue 3–4, pp 239–251 | Cite as

The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme

  • J. Boëthius
  • H. Blomgren
  • V. P. Collins
  • T. Greitz
  • H. Strander
Article

Summary

This report presents the results of a phase I trial of the value of human leucocyte inferon-alpha in the treatment of glioblastoma. Twelve patients entered the trial. In one case we believe that the patient benefitted from the interferon treatment. CT scans of patients on interferon did not reveal the true extent of the tumorous tissue.

Keywords

Glioblastoma multiforme human interferon 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tönnis, W., Walter, W., Das Glioblastoma multiforme (Bericht über 2611 Fälle). Acta neurochir. (Wien)6 (1959), 40–46.Google Scholar
  2. 2.
    Jelsma, R., Bucy, P. C., The treatment of glioblastoma multiforme of the brain. J. Neurosurg.27 (1967), 388–400.PubMedGoogle Scholar
  3. 3.
    Cianfriglia, F., Pompili, A., Riccio, A., Grassi, A. X., CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme. Cancer45 (1980), 1289–1299.PubMedGoogle Scholar
  4. 4.
    Hendler, F. J., Hanlon, K., Hekmatpanah, J., Griem, M. L., Duda, E. E., Mulligan, B., Wollman, R. L., Treatment of grade III and IV astrocytomas with BCNU alone and in combination with VM-26 following surgery and radiation therapy. Cancer Treat. Rep.63 (1979), 1707–1711.PubMedGoogle Scholar
  5. 5.
    Mellstedt, H., Ähre, A., Björkholm, M., Holm, G., Johansson, B., Strander, H., Interferon therapy in myelomatosis. Lancet1 (1979), 245–247.PubMedGoogle Scholar
  6. 6.
    Gutterman, J. U., Blumenschein, G. R., Alexanian, R., Yap, H. Y., Buzdar, A. V., Cavanillas, F., Hortobagyi, G. N., Distefano, A., Hersh, E. M., Rasmussen, S. L., Harmon, M., Pestka, S., Leukocyte interferon induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann. Intern. Med.93 (1980), 399–406.PubMedGoogle Scholar
  7. 7.
    Blomgren, H., Cantell, K, Johansson, B., Lagergren, C., Ringborg, U., Strander, H., Interferon therapy in Hodgkin's disease. Acta Med. Scand.199 (1976), 527–532.PubMedGoogle Scholar
  8. 8.
    Merigan, T. C., Sikova, K., Breeden, J. H., Levy, R., Rosenberg, S. A., A tumor reducing effect of human leukocyte interferon in non-Hodgkin's lymphoma. New Engl. J. Med.299 (1978), 1449–1453.PubMedGoogle Scholar
  9. 9.
    Hill, N., Loeb, E., Pardue, A. S., Dorn, G. L., Khan, A., Hill, J. M., Response of acute leukemia to leukocyte interferon. J. Clin. Hemat. Oncol.9 (1979), 137–149.Google Scholar
  10. 10.
    Einhorn, N., Cantell, K., Einhorn, S., Strander, H., Human leukocyte interferon therapy for advanced ovarian carcinoma. Am. J. Clin. Oncol.5 (1982), 167–172.PubMedGoogle Scholar
  11. 11.
    Cantell, K., Hirvonen, S., Koistinen, V., Partial purification of human leukocyte interferon on a large scale. Methods in Enzymology78 (1981), 499–505.PubMedGoogle Scholar
  12. 12.
    Strander, H., Cantell, K., Production of interferon by human leukocytes in vitro. Ann. Med. Exp. Fenn.44 (1966), 265–273.PubMedGoogle Scholar
  13. 13.
    Zülch, K. J., Histological typing of tumors of the central nervous system. International histological classification of tumors No. 21. WHO, Geneva, 1979.Google Scholar
  14. 14.
    Kernohan, J. W., Sayre, G. P., Tumors of the central nervous system. Atlas of tumor pathology, Section X, Fascicles 35, qand 37. Washington: Armed Forces Institute of Pathology. 1952.Google Scholar
  15. 15.
    Strömblad, L. G., Brun, A., Nordström, C.-H., Salford, L., Sandberg, M., Intratumoral och generell interferonbehandling av astrocytom III–IV. Abstract from Läkaresällskapets Riksstämma 1981.Google Scholar
  16. 16.
    Nagi, M., Araik, T., Kohno, S., Kohase, M., Interferon therapy for malignant brain tumors. In: The clinical potential of interferons (Kono, R., Vilček, J., eds.), pp. 257–272. Tokyo University Press. 1982.Google Scholar
  17. 17.
    Nakamura, O., Takakura, K., Kobayashi, S., Effect on human interferonbeta in the treatment of malignant brain tumors. UCLA Symp. Molecular Cell Biol.24 (1982), 465–477.Google Scholar
  18. 18.
    Suddith, R. L., Kelley, P. J., Hutchinson, H. T., Murray, E. A., Haber, B., In vitro demonstration of an endothelial proliferation factor produced by neural cell lines. Science190 (1975), 682–684.PubMedGoogle Scholar
  19. 19.
    Kelly, P. J., Suddith, R. L., Hutchinson, K., Werrbach, K., Haber, B., Endothelial growth factor present in tissue culture of CNS tumors. J. Neurosurg.44 (1976), 342–346.PubMedGoogle Scholar
  20. 20.
    Folkman, J., Cotran, R., Relation of vascular proliferation of tumor growth. Int. Rev. Exp. Path.16 (1976), 207–248.PubMedGoogle Scholar
  21. 21.
    Zetter, B. R., Migration of capillary endothelial cells is stimulated by tumor-derived factors. Nature285 (1980), 41–43.PubMedGoogle Scholar
  22. 22.
    Brouty-Boyé, D., Zetter, B. R., Inhibition of cell motility by interferon. Science208 (1980), 516–518.PubMedGoogle Scholar
  23. 23.
    Gresser, I., Antitumor effects of interferon. In: Cancer—a comprehensive treatise. Chemotherapy, Vol. 51, pp. 525–571. New York: Plenum Publ. Corp. 1977.Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • J. Boëthius
    • 1
  • H. Blomgren
    • 2
  • V. P. Collins
    • 3
  • T. Greitz
    • 4
  • H. Strander
    • 2
  1. 1.Department of NeurosurgeryKarolinska HospitalStockholmSweden
  2. 2.Department of RadiumhemmetKarolinska HospitalStockholmSweden
  3. 3.Department of Tumour PathologyKarolinska HospitalStockholmSweden
  4. 4.Department of NeuroradiologyKarolinska HospitalStockholmSweden

Personalised recommendations